Benralizumab Proves Noninferior to Mepolizumab for EGPA ...Middle East

Medscape - News
Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab (Nucala) in a head-to-head phase 3 trial of the two drugs. MDedge News

Hence then, the article about benralizumab proves noninferior to mepolizumab for egpa was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Benralizumab Proves Noninferior to Mepolizumab for EGPA )

Apple Storegoogle play

Last updated :

Also on site :